Initial Data of LUCIDITY Study
Recent News
TauRx Pharmaceuticals Ltd., a global leader in tau-based research in Alzheimer’s disease (AD), presented the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference in Lisbon, Portugal.
Mar 07, 2024
Today is the United Nations International Day of Women and Girls in Science. The day is marked every year on February 11 to ensure equal access and participation for women and girls in science.
Feb 11, 2024
TauRx announces it will present the 24-month data from its Phase III LUCIDITY trial at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
Feb 06, 2024
Professor Claude Wischik, co-founder and Chief Executive at TauRx, today contributed to a panel discussion for “Next steps for UK university spin-outs and commercialisation”.
Dec 11, 2023